Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for S Biomedics Co., Ltd. (304360:KRX), powered by AI.
S Biomedics Co., Ltd. is currently trading at ₩34,100. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for S Biomedics Co., Ltd. on Alpha Lenz.
S Biomedics Co., Ltd.'s P/E ratio is -52.0.
“S Biomedics Co., Ltd. trades at a P/E of -52.0 (undervalued) with modest ROE of -79.1%. 3Y revenue CAGR of 11.0% highlights clear growth momentum.”
Ask for details →S Biomedics Co., Ltd. is a biotechnology company engaged in the research and development of cutting-edge biomedical products. The primary focus of S Biomedics is on creating innovative solutions within the field of regenerative medicine. This involves the production of advanced therapeutic products, including stem cell-based therapies, aiming to address substantial medical needs in regenerative treatment areas. The company's research and technological advancements have the potential to significantly impact the healthcare and life sciences industries, particularly in improving patient outcomes through advanced medical treatments. S Biomedics seeks to leverage its expertise in biomedicine to contribute meaningfully to the medical sector by providing state-of-the-art products designed to repair and regenerate damaged tissues. Serving both domestic and international markets, the company positions itself at the forefront of biotechnological innovation, emphasizing rigorous R&D and a commitment to pushing the boundaries of medical science. Its role in the financial market reflects the growing interest and investment in the biotechnological sector, driven by the promise of transformative healthcare solutions.
“S Biomedics Co., Ltd. trades at a P/E of -52.0 (undervalued) with modest ROE of -79.1%. 3Y revenue CAGR of 11.0% highlights clear growth momentum.”
Ask for details →S Biomedics Co., Ltd. (ticker: 304360) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $422.3B.
The current price is ₩34,100 with a P/E ratio of -52x and P/B of 48.68x.
ROE is -79.08% and operating margin is -50.42%. Annual revenue is $16.5B.